Pfizer Has Gotten Better at Developing Drugs. Here's Why

Pfizer (NYSE: PFE) presented some interesting statistics during its fourth-quarter earnings report that showed the company has increased its success rate for getting drugs through clinical development. In this video from Motley Fool Live, recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss why Pfizer is having a change in fortune. While the company may actually be getting better than its peers, the pharma giant could just be getting lucky, and its choice of easier-to-treat diseases certainly helps boost its success rate.